STOCK TITAN

Maplight Therapeutics (NASDAQ: MPLT) holder files to sell 152,230 shares under Rule 144

(Neutral)
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Maplight Therapeutics, Inc. shareholder Christopher Kroeger has filed to sell up to 152,230 common shares through broker Jefferies LLC, with an aggregate market value of 5,771,039.30, on or after July 15, 2026 on the NASDAQ market. The notice lists 42,620,000 common shares outstanding. It also details the acquisition history of the shares, including several Restricted Stock Unit grants from 2023 to 2025. In addition, it itemizes prior sales by Kroeger over the past three months, including a sale of 118,235 shares on May 18, 2026 for 3,215,511.97 and several smaller trades in April and May 2026.

Positive

  • None.

Negative

  • None.
Shares to be sold 152230 shares Number of Maplight Therapeutics common shares covered by the planned sale
Aggregate market value 5771039.30 Aggregate market value of the 152,230 shares to be sold
Shares outstanding 42620000 shares Maplight Therapeutics common shares outstanding as referenced in the notice
Approximate sale date 07/15/2026 Planned date for sale of the covered shares on NASDAQ
Largest recent sale shares 118235 shares Shares sold by Christopher Kroeger on 05/18/2026
Largest recent sale proceeds 3215511.97 Gross proceeds from the 118,235-share sale on 05/18/2026
Restricted Stock Unit Grant financial
"Common | 05/02/2024 | Restricted Stock Unit Grant | Maplight Therapeutics, Inc."
aggregate market value financial
"152230 | 5771039.30 | 42620000 | 07/15/2026 | NASDAQ"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Securities To Be Sold regulatory
"144: Securities To Be Sold Common | 05/02/2024 | Restricted Stock Unit Grant"
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months Christopher Kroeger"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

How many Maplight Therapeutics (MPLT) shares are planned for sale under this notice?

The notice covers a planned sale of up to 152,230 common shares of Maplight Therapeutics, Inc. These shares are to be sold through broker Jefferies LLC on or after July 15, 2026 on the NASDAQ market.

What is the aggregate market value of the Maplight Therapeutics (MPLT) shares to be sold?

The planned sale has an aggregate market value of 5,771,039.30. This figure represents the total market value of the 152,230 Maplight Therapeutics common shares covered by the sale notice filed by shareholder Christopher Kroeger.

How many Maplight Therapeutics (MPLT) shares are outstanding according to this notice?

The notice states that there are 42,620,000 Maplight Therapeutics common shares outstanding. This figure provides context for the planned sale of 152,230 shares, showing the sale as a portion of the company’s total outstanding equity.

Who is the selling shareholder and broker in this Maplight Therapeutics (MPLT) transaction?

The selling shareholder is Christopher Kroeger, and the broker handling the transaction is Jefferies LLC. Jefferies LLC is identified with its New York address, and the shares are to be sold on the NASDAQ market.

What prior Maplight Therapeutics (MPLT) share sales are disclosed for the past 3 months?

The notice lists multiple sales by Christopher Kroeger between April 15 and May 18, 2026, including 118,235 shares sold on May 18, 2026 for 3,215,511.97, along with several smaller transactions in April and early May.

What types of acquisitions funded the Maplight Therapeutics (MPLT) shares being sold?

The shares trace back to several Restricted Stock Unit grants from 2023 to 2025. The notice lists RSU grants dated July 30, 2023, November 9, 2023, May 2, 2024, and July 18, 2025, each with associated share amounts acquired.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature